Vyteris gets grant for smart patch; Cedars-Sinai targets brain tumors

> Vyteris has received a $489,000 grant under the U.S. Qualifying Therapeutic Discovery Project program. The money will be used to advance Vyteris' smart patch drug delivery technology for female infertility and diabetes. Vyteris release

> A Cedars-Sinai research team has created a "nanobioconjugate" drug that may be given by intravenous injection and carried in the blood to target brain tumors. It is engineered to specifically permeate the tumor cell wall, entering endosomes, mobile compartments within cells. Report

> Nuvo Research, which focuses on topical and transdermal drug delivery technologies, has announced that its Phase II clinical trials in Europe evaluating its drug WF10 as a treatment for severe allergic rhinitis has met its primary endpoint. The trial assessed the efficacy and safety of WF10 infusions for the treatment of patients with severe persistent allergic rhinitis. Nuvo release

> According to companiesandmarkets.com, Novartis leads the $5.6 billion transdermal drug delivery market. Item

> Drug delivery abstract of the week: Engineering Liposomes and Nanoparticles for Biological Targeting. Abstract

> Drug delivery patent application of the week: Nanocell drug delivery system. Patent application

> Drug delivery video of the week: Facilitating Drug Delivery to the Brain--Big Ideas 2010--Enterprise Ireland. Video

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.